ALIBABA-CLOUD
10.1.2023 07:01:39 CET | Business Wire | Press release
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, has announced the launch of Apsara Developer Community, a new hub created to support global developers through an enhanced provision of diverse developer tools and resources. It aims to support the continuous growth of the developer community, while facilitating the further progress of the digital economy across markets.
“The developer community is an integral part of Alibaba Cloud’s ecosystem. We hope to grow together with our developers by providing the latest technologies, ecosystem resources and business collaboration opportunities,” said Selina Yuan, Vice President of Alibaba Group and President of Alibaba Cloud Intelligence International Business Unit.
New and Enhanced Community Resources, Competitions and Scholarship for Global Developers
Unveiled at Alibaba Cloud’s Global Developer Summit at Jakarta today, The Apsara Developer Community offers global developers resources and insights into the rising technology trends ranging from Web3, AI to digital intelligence. These resources include access to a slew of new development tools and latest projects, training materials and tutorials, forums and blogs, community events and competitions to showcase their application development, and other upskilling and networking opportunities.
The cloud leader also announced its latest competition, PolarDB Global Hackathon 2023, to encourage developers to explore cloud-native database innovations. From now until February 28, participants can submit their projects and winners will be awarded with a total of US$30,000 in cash prizes.
In addition, Alibaba Cloud also unveiled the Alibaba SMART Scholarship, which aims to encourage students to join the developer community with cloud-based technologies and become local digital talents. During the first year of this annual scholarship program, 20 interns from universities will be recruited to join Alibaba Cloud’s local offices to gain more field experience.
New Solution to Facilitate Superapp Development
With the rise of superapps – apps that include a range of independently developed miniapps to cater for different user requirements – Alibaba Cloud also unveiled a new solution to help developers build superapps cost-effectively and efficiently. Leveraging Alibaba Cloud’s Enterprise Mobile Application Studio (EMAS), the solution aims to enable developers to swiftly build superapps with rich platform capabilities within hours, adding competitive advantages for global organisations and enterprises.
Derived from the best practices of Alibaba’s e-commerce superapps Taobao and Tmall, the comprehensive solution provides developers with a rich ecosystem, including components for app infrastructure and business features, containers for running miniapps, and services for DevOps and operations.
“We believe our proven technologies and experience in supporting successful superapps can be beneficial for worldwide developers who are looking to create their own superapps and corresponding platform ecosystem,” said Raymond Xiao, Head of International Industry Solutions and Architecture at Alibaba Cloud Intelligence. “We can co-create more innovative technologies and solutions together with our developers, boosting further growth of the developer community.”
Alibaba Cloud is dedicated to contributing to the developer ecosystem including the open-source community. Alibaba Cloud, with over 30,000 contributors, has contributed to over 2,700 open-source projects on Github. The leading cloud provider is also a key member in various open-source communities such as Cloud Native Computing Foundation (CNCF), The Linux Foundation and RISC-V International.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com) is the digital technology and intelligence backbone of Alibaba Group. It offers a complete suite of cloud services to customers worldwide, including elastic computing, database, storage, network virtualization services, large-scale computing, security, management and application services, big data analytics, a machine learning platform and IoT services. Alibaba Cloud is China’s leading provider of public cloud services by revenue in 2019, including PaaS and IaaS services, according to IDC. Alibaba Group is the world’s third leading and Asia Pacific’s leading IaaS provider by revenue in 2020 in U.S. dollars, according to Gartner’s April 2021 report.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005670/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom